Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Inclusion Criteria: Part I : * Male or female healthy volunteers 18 to 45 years of age (inclusive). * Subjects with a body mass index (BMI) ≥ 18 and ≤ 28 kg/m2 at screening. * For female subjects of childbearing potential, use of double contraception method. * Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. Part II and III : * Male healthy volunteers 18 to 55 years of age (inclusive). * Subjects with a BMI \>28 and \<35 kg/m2 at screening. * Normal arterial BP and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. Part IV : * Male or female Type 2 diabetic patients 18 to 60 years of age. * Females participating in the study must be either of non-child bearing potential or using an efficient double contraception. * Currently treated with any antidiabetic treatment (a maximum of two anti-diabetic drugs including metformin in all cases) with the exception of insulin or GLP analogs and agonists therapy. * Stable diabetes with glycosylated hemoglobin (HbA1c) \< or =10% or less. * Normal renal function as defined by a creatine clearance \>90 mL/min calculated with the Cockcroft-Gault formula. * Subjects with a BMI from 18 to 32 kg/m2 at screening. Exclusion Criteria: Part I : * Who previously received GFT505. * With any clinically significant abnormality following review of prestudy laboratory tests (Aspartate and Alanine aminotransferase must be within normal ranges), vital signs, full physical examination and Electrocardiogram. * Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 (Human immunodeficiency virus) or anti-HCV (Hepatitis C virus) antibodies. * Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol). * Who drink more than 8 cups daily of beverage containing caffeine. * Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines). * Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study. * Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration. Part II and III : specific additional exclusion criteria \- Who have taken fibrates within 6 weeks prior to the first dose administration. Part IV : specific additional exclusion criteria * With unstable proliferative retinopathy, macular oedema (fundus examination performed in the previous year will be considered relevant on Investigator's judgement). * Who have taken fibrates within 6 weeks prior to the first dose administration.